GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Other Operating Expense

ValiRx (LSE:VAL) Other Operating Expense : £-0.03 Mil (TTM As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Other Operating Expense?

ValiRx's Other Operating Expense for the six months ended in Dec. 2024 was £-0.05 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was £-0.03 Mil.

ValiRx's quarterly Other Operating Expense increased from Dec. 2023 (£0.02 Mil) to Jun. 2024 (£0.02 Mil) but then declined from Jun. 2024 (£0.02 Mil) to Dec. 2024 (£-0.05 Mil).

ValiRx's annual Other Operating Expense declined from Dec. 2022 (£0.54 Mil) to Dec. 2023 (£0.04 Mil) and declined from Dec. 2023 (£0.04 Mil) to Dec. 2024 (£-0.03 Mil).


ValiRx Other Operating Expense Historical Data

The historical data trend for ValiRx's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Other Operating Expense Chart

ValiRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 0.16 0.54 0.04 -0.03

ValiRx Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.02 0.02 0.02 -0.05

ValiRx Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx Other Operating Expense Related Terms

Thank you for viewing the detailed overview of ValiRx's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx Business Description

Industry
Traded in Other Exchanges
N/A
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.